Similarly, if SHP2 inhibitors indeed turn out to enhance insulin sensitivity in clinical trials, they could potentially be useful to offset the deleterious, hypoglycaemic effects of anti-cancer PI3K inhibitors45; or they could be utilized as a component of oral anti-diabetic combinations. The gene discussed is PTPN11; the disease is cancer.